 | • レポートコード：MRC2-11QY01679 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、181ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はB型インフルエンザ感染症治療薬のグローバル市場について調査・分析したレポートです。種類別（APP-309、CF-403、GC-3106A、KIN-1400、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別B型インフルエンザ感染症治療薬の競争状況、市場シェア ・世界のB型インフルエンザ感染症治療薬市場：種類別市場規模 2015年-2020年（APP-309、CF-403、GC-3106A、KIN-1400、その他） ・世界のB型インフルエンザ感染症治療薬市場：種類別市場規模予測 2021年-2026年（APP-309、CF-403、GC-3106A、KIN-1400、その他） ・世界のB型インフルエンザ感染症治療薬市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界のB型インフルエンザ感染症治療薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米のB型インフルエンザ感染症治療薬市場分析：米国、カナダ ・ヨーロッパのB型インフルエンザ感染症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのB型インフルエンザ感染症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のB型インフルエンザ感染症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのB型インフルエンザ感染症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AbbVie Inc、Adimmune Corp、Altravax Inc、Amarillo Biosciences Inc、Aphios Corp、BioCryst Pharmaceuticals Inc、Cadila Healthcare Ltd、ContraFect Corp、Daiichi Sankyo Company Ltd、Fujifilm Holdings Corporation、GlaxoSmithKline Plc、Green Cross Corp、Inovio Pharmaceuticals Inc、Kineta Inc、Medicago Inc、MedImmune LLC、Mucosis BV、Novavax Inc、Park Active Molecules、Romark Laboratories LC、Sanofi、Sanofi Pasteur SA、Shionogi & Co Ltd、SK Chemicals Co Ltd、TSRL Inc、Vaxart Inc、Vectura Group Plc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Influenzavirus B Infection Drug Market
The global Influenzavirus B Infection Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Influenzavirus B Infection Drug Scope and Market Size
Influenzavirus B Infection Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Influenzavirus B Infection Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Influenzavirus B Infection Drug market is segmented into
APP-309
CF-403
GC-3106A
KIN-1400
Others
Segment by Application, the Influenzavirus B Infection Drug market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Influenzavirus B Infection Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Influenzavirus B Infection Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Influenzavirus B Infection Drug Market Share Analysis
Influenzavirus B Infection Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Influenzavirus B Infection Drug business, the date to enter into the Influenzavirus B Infection Drug market, Influenzavirus B Infection Drug product introduction, recent developments, etc.
The major vendors covered:
AbbVie Inc
Adimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioCryst Pharmaceuticals Inc
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Company Ltd
Fujifilm Holdings Corporation
GlaxoSmithKline Plc
Green Cross Corp
Inovio Pharmaceuticals Inc
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Park Active Molecules
Romark Laboratories LC
Sanofi
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc
1 Study Coverage
1.1 Influenzavirus B Infection Drug Product Introduction
1.2 Market Segments
1.3 Key Influenzavirus B Infection Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Type
1.4.2 APP-309
1.4.3 CF-403
1.4.4 GC-3106A
1.4.5 KIN-1400
1.4.6 Others
1.5 Market by Application
1.5.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Influenzavirus B Infection Drug Market Size, Estimates and Forecasts
2.1.1 Global Influenzavirus B Infection Drug Revenue 2015-2026
2.1.2 Global Influenzavirus B Infection Drug Sales 2015-2026
2.2 Global Influenzavirus B Infection Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Influenzavirus B Infection Drug Competitor Landscape by Players
3.1 Influenzavirus B Infection Drug Sales by Manufacturers
3.1.1 Influenzavirus B Infection Drug Sales by Manufacturers (2015-2020)
3.1.2 Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Influenzavirus B Infection Drug Revenue by Manufacturers
3.2.1 Influenzavirus B Infection Drug Revenue by Manufacturers (2015-2020)
3.2.2 Influenzavirus B Infection Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Influenzavirus B Infection Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Influenzavirus B Infection Drug Revenue in 2019
3.2.5 Global Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Influenzavirus B Infection Drug Price by Manufacturers
3.4 Influenzavirus B Infection Drug Manufacturing Base Distribution, Product Types
3.4.1 Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Influenzavirus B Infection Drug Product Type
3.4.3 Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Influenzavirus B Infection Drug Market Size by Type (2015-2020)
4.1.1 Global Influenzavirus B Infection Drug Sales by Type (2015-2020)
4.1.2 Global Influenzavirus B Infection Drug Revenue by Type (2015-2020)
4.1.3 Influenzavirus B Infection Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Influenzavirus B Infection Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Type (2021-2026)
4.2.3 Influenzavirus B Infection Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Influenzavirus B Infection Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Influenzavirus B Infection Drug Market Size by Application (2015-2020)
5.1.1 Global Influenzavirus B Infection Drug Sales by Application (2015-2020)
5.1.2 Global Influenzavirus B Infection Drug Revenue by Application (2015-2020)
5.1.3 Influenzavirus B Infection Drug Price by Application (2015-2020)
5.2 Influenzavirus B Infection Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Influenzavirus B Infection Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Influenzavirus B Infection Drug by Country
6.1.1 North America Influenzavirus B Infection Drug Sales by Country
6.1.2 North America Influenzavirus B Infection Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Influenzavirus B Infection Drug Market Facts & Figures by Type
6.3 North America Influenzavirus B Infection Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Influenzavirus B Infection Drug by Country
7.1.1 Europe Influenzavirus B Infection Drug Sales by Country
7.1.2 Europe Influenzavirus B Infection Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Influenzavirus B Infection Drug Market Facts & Figures by Type
7.3 Europe Influenzavirus B Infection Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Influenzavirus B Infection Drug by Region
8.1.1 Asia Pacific Influenzavirus B Infection Drug Sales by Region
8.1.2 Asia Pacific Influenzavirus B Infection Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Influenzavirus B Infection Drug Market Facts & Figures by Type
8.3 Asia Pacific Influenzavirus B Infection Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Influenzavirus B Infection Drug by Country
9.1.1 Latin America Influenzavirus B Infection Drug Sales by Country
9.1.2 Latin America Influenzavirus B Infection Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Influenzavirus B Infection Drug Market Facts & Figures by Type
9.3 Central & South America Influenzavirus B Infection Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Influenzavirus B Infection Drug by Country
10.1.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Country
10.1.2 Middle East and Africa Influenzavirus B Infection Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Influenzavirus B Infection Drug Market Facts & Figures by Type
10.3 Middle East and Africa Influenzavirus B Infection Drug Market Facts & Figures by Application
11 Company Profiles
11.1 AbbVie Inc
11.1.1 AbbVie Inc Corporation Information
11.1.2 AbbVie Inc Description and Business Overview
11.1.3 AbbVie Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered
11.1.5 AbbVie Inc Related Developments
11.2 Adimmune Corp
11.2.1 Adimmune Corp Corporation Information
11.2.2 Adimmune Corp Description and Business Overview
11.2.3 Adimmune Corp Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Adimmune Corp Influenzavirus B Infection Drug Products Offered
11.2.5 Adimmune Corp Related Developments
11.3 Altravax Inc
11.3.1 Altravax Inc Corporation Information
11.3.2 Altravax Inc Description and Business Overview
11.3.3 Altravax Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Altravax Inc Influenzavirus B Infection Drug Products Offered
11.3.5 Altravax Inc Related Developments
11.4 Amarillo Biosciences Inc
11.4.1 Amarillo Biosciences Inc Corporation Information
11.4.2 Amarillo Biosciences Inc Description and Business Overview
11.4.3 Amarillo Biosciences Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Products Offered
11.4.5 Amarillo Biosciences Inc Related Developments
11.5 Aphios Corp
11.5.1 Aphios Corp Corporation Information
11.5.2 Aphios Corp Description and Business Overview
11.5.3 Aphios Corp Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Aphios Corp Influenzavirus B Infection Drug Products Offered
11.5.5 Aphios Corp Related Developments
11.6 BioCryst Pharmaceuticals Inc
11.6.1 BioCryst Pharmaceuticals Inc Corporation Information
11.6.2 BioCryst Pharmaceuticals Inc Description and Business Overview
11.6.3 BioCryst Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Products Offered
11.6.5 BioCryst Pharmaceuticals Inc Related Developments
11.7 Cadila Healthcare Ltd
11.7.1 Cadila Healthcare Ltd Corporation Information
11.7.2 Cadila Healthcare Ltd Description and Business Overview
11.7.3 Cadila Healthcare Ltd Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Products Offered
11.7.5 Cadila Healthcare Ltd Related Developments
11.8 ContraFect Corp
11.8.1 ContraFect Corp Corporation Information
11.8.2 ContraFect Corp Description and Business Overview
11.8.3 ContraFect Corp Sales, Revenue and Gross Margin (2015-2020)
11.8.4 ContraFect Corp Influenzavirus B Infection Drug Products Offered
11.8.5 ContraFect Corp Related Developments
11.9 Daiichi Sankyo Company Ltd
11.9.1 Daiichi Sankyo Company Ltd Corporation Information
11.9.2 Daiichi Sankyo Company Ltd Description and Business Overview
11.9.3 Daiichi Sankyo Company Ltd Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Products Offered
11.9.5 Daiichi Sankyo Company Ltd Related Developments
11.10 Fujifilm Holdings Corporation
11.10.1 Fujifilm Holdings Corporation Corporation Information
11.10.2 Fujifilm Holdings Corporation Description and Business Overview
11.10.3 Fujifilm Holdings Corporation Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Products Offered
11.10.5 Fujifilm Holdings Corporation Related Developments
11.1 AbbVie Inc
11.1.1 AbbVie Inc Corporation Information
11.1.2 AbbVie Inc Description and Business Overview
11.1.3 AbbVie Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered
11.1.5 AbbVie Inc Related Developments
11.12 Green Cross Corp
11.12.1 Green Cross Corp Corporation Information
11.12.2 Green Cross Corp Description and Business Overview
11.12.3 Green Cross Corp Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Green Cross Corp Products Offered
11.12.5 Green Cross Corp Related Developments
11.13 Inovio Pharmaceuticals Inc
11.13.1 Inovio Pharmaceuticals Inc Corporation Information
11.13.2 Inovio Pharmaceuticals Inc Description and Business Overview
11.13.3 Inovio Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Inovio Pharmaceuticals Inc Products Offered
11.13.5 Inovio Pharmaceuticals Inc Related Developments
11.14 Kineta Inc
11.14.1 Kineta Inc Corporation Information
11.14.2 Kineta Inc Description and Business Overview
11.14.3 Kineta Inc Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Kineta Inc Products Offered
11.14.5 Kineta Inc Related Developments
11.15 Medicago Inc
11.15.1 Medicago Inc Corporation Information
11.15.2 Medicago Inc Description and Business Overview
11.15.3 Medicago Inc Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Medicago Inc Products Offered
11.15.5 Medicago Inc Related Developments
11.16 MedImmune LLC
11.16.1 MedImmune LLC Corporation Information
11.16.2 MedImmune LLC Description and Business Overview
11.16.3 MedImmune LLC Sales, Revenue and Gross Margin (2015-2020)
11.16.4 MedImmune LLC Products Offered
11.16.5 MedImmune LLC Related Developments
11.17 Mucosis BV
11.17.1 Mucosis BV Corporation Information
11.17.2 Mucosis BV Description and Business Overview
11.17.3 Mucosis BV Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Mucosis BV Products Offered
11.17.5 Mucosis BV Related Developments
11.18 Novavax Inc
11.18.1 Novavax Inc Corporation Information
11.18.2 Novavax Inc Description and Business Overview
11.18.3 Novavax Inc Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Novavax Inc Products Offered
11.18.5 Novavax Inc Related Developments
11.19 Park Active Molecules
11.19.1 Park Active Molecules Corporation Information
11.19.2 Park Active Molecules Description and Business Overview
11.19.3 Park Active Molecules Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Park Active Molecules Products Offered
11.19.5 Park Active Molecules Related Developments
11.20 Romark Laboratories LC
11.20.1 Romark Laboratories LC Corporation Information
11.20.2 Romark Laboratories LC Description and Business Overview
11.20.3 Romark Laboratories LC Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Romark Laboratories LC Products Offered
11.20.5 Romark Laboratories LC Related Developments
11.21 Sanofi
11.21.1 Sanofi Corporation Information
11.21.2 Sanofi Description and Business Overview
11.21.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Sanofi Products Offered
11.21.5 Sanofi Related Developments
11.22 Sanofi Pasteur SA
11.22.1 Sanofi Pasteur SA Corporation Information
11.22.2 Sanofi Pasteur SA Description and Business Overview
11.22.3 Sanofi Pasteur SA Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Sanofi Pasteur SA Products Offered
11.22.5 Sanofi Pasteur SA Related Developments
11.23 Shionogi & Co Ltd
11.23.1 Shionogi & Co Ltd Corporation Information
11.23.2 Shionogi & Co Ltd Description and Business Overview
11.23.3 Shionogi & Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Shionogi & Co Ltd Products Offered
11.23.5 Shionogi & Co Ltd Related Developments
11.24 SK Chemicals Co Ltd
11.24.1 SK Chemicals Co Ltd Corporation Information
11.24.2 SK Chemicals Co Ltd Description and Business Overview
11.24.3 SK Chemicals Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.24.4 SK Chemicals Co Ltd Products Offered
11.24.5 SK Chemicals Co Ltd Related Developments
11.25 TSRL Inc
11.25.1 TSRL Inc Corporation Information
11.25.2 TSRL Inc Description and Business Overview
11.25.3 TSRL Inc Sales, Revenue and Gross Margin (2015-2020)
11.25.4 TSRL Inc Products Offered
11.25.5 TSRL Inc Related Developments
11.26 Vaxart Inc
11.26.1 Vaxart Inc Corporation Information
11.26.2 Vaxart Inc Description and Business Overview
11.26.3 Vaxart Inc Sales, Revenue and Gross Margin (2015-2020)
11.26.4 Vaxart Inc Products Offered
11.26.5 Vaxart Inc Related Developments
11.27 Vectura Group Plc
11.27.1 Vectura Group Plc Corporation Information
11.27.2 Vectura Group Plc Description and Business Overview
11.27.3 Vectura Group Plc Sales, Revenue and Gross Margin (2015-2020)
11.27.4 Vectura Group Plc Products Offered
11.27.5 Vectura Group Plc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Influenzavirus B Infection Drug Market Estimates and Projections by Region
12.1.1 Global Influenzavirus B Infection Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Influenzavirus B Infection Drug Revenue Forecast by Regions 2021-2026
12.2 North America Influenzavirus B Infection Drug Market Size Forecast (2021-2026)
12.2.1 North America: Influenzavirus B Infection Drug Sales Forecast (2021-2026)
12.2.2 North America: Influenzavirus B Infection Drug Revenue Forecast (2021-2026)
12.2.3 North America: Influenzavirus B Infection Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Influenzavirus B Infection Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Influenzavirus B Infection Drug Sales Forecast (2021-2026)
12.3.2 Europe: Influenzavirus B Infection Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Influenzavirus B Infection Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Influenzavirus B Infection Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Influenzavirus B Infection Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Influenzavirus B Infection Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Influenzavirus B Infection Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Influenzavirus B Infection Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Influenzavirus B Infection Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Influenzavirus B Infection Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Influenzavirus B Infection Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Influenzavirus B Infection Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Influenzavirus B Infection Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Influenzavirus B Infection Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Influenzavirus B Infection Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Influenzavirus B Infection Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Influenzavirus B Infection Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Influenzavirus B Infection Drug Market Segments
Table 2. Ranking of Global Top Influenzavirus B Infection Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Influenzavirus B Infection Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of APP-309
Table 5. Major Manufacturers of CF-403
Table 6. Major Manufacturers of GC-3106A
Table 7. Major Manufacturers of KIN-1400
Table 8. Major Manufacturers of Others
Table 9. Global Influenzavirus B Infection Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Influenzavirus B Infection Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Influenzavirus B Infection Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Influenzavirus B Infection Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Influenzavirus B Infection Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Influenzavirus B Infection Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Influenzavirus B Infection Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Influenzavirus B Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Influenzavirus B Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenzavirus B Infection Drug as of 2019)
Table 18. Influenzavirus B Infection Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Influenzavirus B Infection Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Influenzavirus B Infection Drug Price (2015-2020) (USD/Pcs)
Table 21. Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Influenzavirus B Infection Drug Product Type
Table 23. Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Influenzavirus B Infection Drug Sales Share by Type (2015-2020)
Table 27. Global Influenzavirus B Infection Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Influenzavirus B Infection Drug Revenue Share by Type (2015-2020)
Table 29. Influenzavirus B Infection Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Influenzavirus B Infection Drug Sales Share by Application (2015-2020)
Table 32. North America Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 34. North America Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
Table 38. North America Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Influenzavirus B Infection Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Influenzavirus B Infection Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
Table 72. AbbVie Inc Corporation Information
Table 73. AbbVie Inc Description and Major Businesses
Table 74. AbbVie Inc Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. AbbVie Inc Product
Table 76. AbbVie Inc Recent Development
Table 77. Adimmune Corp Corporation Information
Table 78. Adimmune Corp Description and Major Businesses
Table 79. Adimmune Corp Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Adimmune Corp Product
Table 81. Adimmune Corp Recent Development
Table 82. Altravax Inc Corporation Information
Table 83. Altravax Inc Description and Major Businesses
Table 84. Altravax Inc Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Altravax Inc Product
Table 86. Altravax Inc Recent Development
Table 87. Amarillo Biosciences Inc Corporation Information
Table 88. Amarillo Biosciences Inc Description and Major Businesses
Table 89. Amarillo Biosciences Inc Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Amarillo Biosciences Inc Product
Table 91. Amarillo Biosciences Inc Recent Development
Table 92. Aphios Corp Corporation Information
Table 93. Aphios Corp Description and Major Businesses
Table 94. Aphios Corp Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Aphios Corp Product
Table 96. Aphios Corp Recent Development
Table 97. BioCryst Pharmaceuticals Inc Corporation Information
Table 98. BioCryst Pharmaceuticals Inc Description and Major Businesses
Table 99. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. BioCryst Pharmaceuticals Inc Product
Table 101. BioCryst Pharmaceuticals Inc Recent Development
Table 102. Cadila Healthcare Ltd Corporation Information
Table 103. Cadila Healthcare Ltd Description and Major Businesses
Table 104. Cadila Healthcare Ltd Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Cadila Healthcare Ltd Product
Table 106. Cadila Healthcare Ltd Recent Development
Table 107. ContraFect Corp Corporation Information
Table 108. ContraFect Corp Description and Major Businesses
Table 109. ContraFect Corp Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. ContraFect Corp Product
Table 111. ContraFect Corp Recent Development
Table 112. Daiichi Sankyo Company Ltd Corporation Information
Table 113. Daiichi Sankyo Company Ltd Description and Major Businesses
Table 114. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Daiichi Sankyo Company Ltd Product
Table 116. Daiichi Sankyo Company Ltd Recent Development
Table 117. Fujifilm Holdings Corporation Corporation Information
Table 118. Fujifilm Holdings Corporation Description and Major Businesses
Table 119. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. Fujifilm Holdings Corporation Product
Table 121. Fujifilm Holdings Corporation Recent Development
Table 122. GlaxoSmithKline Plc Corporation Information
Table 123. GlaxoSmithKline Plc Description and Major Businesses
Table 124. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. GlaxoSmithKline Plc Product
Table 126. GlaxoSmithKline Plc Recent Development
Table 127. Green Cross Corp Corporation Information
Table 128. Green Cross Corp Description and Major Businesses
Table 129. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 130. Green Cross Corp Product
Table 131. Green Cross Corp Recent Development
Table 132. Inovio Pharmaceuticals Inc Corporation Information
Table 133. Inovio Pharmaceuticals Inc Description and Major Businesses
Table 134. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 135. Inovio Pharmaceuticals Inc Product
Table 136. Inovio Pharmaceuticals Inc Recent Development
Table 137. Kineta Inc Corporation Information
Table 138. Kineta Inc Description and Major Businesses
Table 139. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 140. Kineta Inc Product
Table 141. Kineta Inc Recent Development
Table 142. Medicago Inc Corporation Information
Table 143. Medicago Inc Description and Major Businesses
Table 144. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 145. Medicago Inc Product
Table 146. Medicago Inc Recent Development
Table 147. MedImmune LLC Corporation Information
Table 148. MedImmune LLC Description and Major Businesses
Table 149. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 150. MedImmune LLC Product
Table 151. MedImmune LLC Recent Development
Table 152. Mucosis BV Corporation Information
Table 153. Mucosis BV Description and Major Businesses
Table 154. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 155. Mucosis BV Product
Table 156. Mucosis BV Recent Development
Table 157. Novavax Inc Corporation Information
Table 158. Novavax Inc Description and Major Businesses
Table 159. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 160. Novavax Inc Product
Table 161. Novavax Inc Recent Development
Table 162. Park Active Molecules Corporation Information
Table 163. Park Active Molecules Description and Major Businesses
Table 164. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 165. Park Active Molecules Product
Table 166. Park Active Molecules Recent Development
Table 167. Romark Laboratories LC Corporation Information
Table 168. Romark Laboratories LC Description and Major Businesses
Table 169. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 170. Romark Laboratories LC Product
Table 171. Romark Laboratories LC Recent Development
Table 172. Sanofi Corporation Information
Table 173. Sanofi Description and Major Businesses
Table 174. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 175. Sanofi Product
Table 176. Sanofi Recent Development
Table 177. Sanofi Pasteur SA Corporation Information
Table 178. Sanofi Pasteur SA Description and Major Businesses
Table 179. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 180. Sanofi Pasteur SA Product
Table 181. Sanofi Pasteur SA Recent Development
Table 182. Shionogi & Co Ltd Corporation Information
Table 183. Shionogi & Co Ltd Description and Major Businesses
Table 184. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 185. Shionogi & Co Ltd Product
Table 186. Shionogi & Co Ltd Recent Development
Table 187. SK Chemicals Co Ltd Corporation Information
Table 188. SK Chemicals Co Ltd Description and Major Businesses
Table 189. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 190. SK Chemicals Co Ltd Product
Table 191. SK Chemicals Co Ltd Recent Development
Table 192. TSRL Inc Corporation Information
Table 193. TSRL Inc Description and Major Businesses
Table 194. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 195. TSRL Inc Product
Table 196. TSRL Inc Recent Development
Table 197. Vaxart Inc Corporation Information
Table 198. Vaxart Inc Description and Major Businesses
Table 199. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 200. Vaxart Inc Product
Table 201. Vaxart Inc Recent Development
Table 202. Vectura Group Plc Corporation Information
Table 203. Vectura Group Plc Description and Major Businesses
Table 204. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 205. Vectura Group Plc Product
Table 206. Vectura Group Plc Recent Development
Table 207. Global Influenzavirus B Infection Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 208. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Regions (2021-2026)
Table 209. Global Influenzavirus B Infection Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 210. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 211. North America: Influenzavirus B Infection Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 212. North America: Influenzavirus B Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 213. Europe: Influenzavirus B Infection Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 214. Europe: Influenzavirus B Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 215. Asia Pacific: Influenzavirus B Infection Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 216. Asia Pacific: Influenzavirus B Infection Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 217. Latin America: Influenzavirus B Infection Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 218. Latin America: Influenzavirus B Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 219. Middle East and Africa: Influenzavirus B Infection Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 220. Middle East and Africa: Influenzavirus B Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 221. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 222. Key Challenges
Table 223. Market Risks
Table 224. Main Points Interviewed from Key Influenzavirus B Infection Drug Players
Table 225. Influenzavirus B Infection Drug Customers List
Table 226. Influenzavirus B Infection Drug Distributors List
Table 227. Research Programs/Design for This Report
Table 228. Key Data Information from Secondary Sources
Table 229. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenzavirus B Infection Drug Product Picture
Figure 2. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2020 & 2026
Figure 3. APP-309 Product Picture
Figure 4. CF-403 Product Picture
Figure 5. GC-3106A Product Picture
Figure 6. KIN-1400 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Influenzavirus B Infection Drug Report Years Considered
Figure 13. Global Influenzavirus B Infection Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Influenzavirus B Infection Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Influenzavirus B Infection Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Influenzavirus B Infection Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Influenzavirus B Infection Drug Sales Market Share by Region in 2019
Figure 18. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Influenzavirus B Infection Drug Revenue Market Share by Region in 2019
Figure 20. Global Influenzavirus B Infection Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Influenzavirus B Infection Drug Revenue in 2019
Figure 22. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2019
Figure 25. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Influenzavirus B Infection Drug Revenue Market Share by Type in 2019
Figure 27. Global Influenzavirus B Infection Drug Market Share by Price Range (2015-2020)
Figure 28. Global Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2019
Figure 30. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Influenzavirus B Infection Drug Revenue Market Share by Application in 2019
Figure 32. North America Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 35. North America Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Influenzavirus B Infection Drug Market Share by Type in 2019
Figure 41. North America Influenzavirus B Infection Drug Market Share by Application in 2019
Figure 42. Europe Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 45. Europe Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 46. Germany Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Influenzavirus B Infection Drug Market Share by Type in 2019
Figure 57. Europe Influenzavirus B Infection Drug Market Share by Application in 2019
Figure 58. Asia Pacific Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Region in 2019
Figure 62. China Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Influenzavirus B Infection Drug Market Share by Type in 2019
Figure 85. Asia Pacific Influenzavirus B Infection Drug Market Share by Application in 2019
Figure 86. Latin America Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 89. Latin America Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Influenzavirus B Infection Drug Market Share by Type in 2019
Figure 97. Latin America Influenzavirus B Infection Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Influenzavirus B Infection Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Influenzavirus B Infection Drug Market Share by Application in 2019
Figure 110. North America Influenzavirus B Infection Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Influenzavirus B Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Influenzavirus B Infection Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Influenzavirus B Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Influenzavirus B Infection Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Influenzavirus B Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Influenzavirus B Infection Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Influenzavirus B Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Influenzavirus B Infection Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Influenzavirus B Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
ジカウイルス感染症治療薬の世界市場（～2026年） It is used to treat various uncomfortable symptoms caused by zika virus infection. Market Analysis and Insights: Global Zika Virus Infection Drug Market The global Zika Virus Infection Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during…- Cディフィシル感染症治療薬の世界市場（～2026年） Market Analysis and Insights: Global C Difficile Infection Drug Market The global C Difficile Infection Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global C Difficile Infection Drug Scope and Market Size C Difficile …
- クレブシエラニューモニエ感染症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Klebsiella Pneumoniae Infection Drug Market The global Klebsiella Pneumoniae Infection Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Klebsiella Pneumoniae Infection Drug Scop…
- 尿路感染症治療の世界市場（～2026年） Urinary tract infection (UTI) is a common infections of the urinary tract, which consists of the kidneys, ureters, bladder, urethra or prostate gland. This trend of increment in the prevalence rate of diabetes among adults is expected to continue during the forecast period. Therefore, with increasin…
- 医療関連感染（HAI）治療の世界市場（～2026年） Hospital Acquired Infection Treatment is an infection that is acquired in a hospital or other health care facility. Market Analysis and Insights: Global Hospital Acquired Infection Treatment Market The global Hospital Acquired Infection Treatment market size is projected to reach US$ 19430 million b…